We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Innovative Von Willebrand Factor Test Launched in US

By LabMedica International staff writers
Posted on 18 Apr 2017
Print article
Image: A ribbon model of von Willebrand factor, mutations of which can cause the inherited blood disorder von Willebrand Disease (Photo courtesy of Wikimedia).
Image: A ribbon model of von Willebrand factor, mutations of which can cause the inherited blood disorder von Willebrand Disease (Photo courtesy of Wikimedia).
A center for blood diseases has launched a new test in the United States to more accurately measure activity of von Willebrand Factor (VWF), one of the blood-clotting proteins, for people with the inherited bleeding disorder von Willebrand disease (VWD).

The new assay – “VWF GPIbM Activity” – was launched by BloodCenter of Wisconsin (Milwaukee, WI, USA), part of Versiti. The test employs patented technology previously not used in the USA that provides more precise measurement of VWF platelet-binding activity – critical for making an accurate diagnosis of VWD. BloodCenter of Wisconsin is the first organization to make this test available in the US in a clinical laboratory setting.

Though there is no cure for VWD, treatment can help prevent or stop bleeding episodes. Making the most accurate diagnosis is critical to identifying the most appropriate treatment to manage the disease.

VWF GPIbM Activity detects qualitative VWF defects, reducing variability and providing more precise, reliable, and sensitive test results. Clinical hematologists can thus be more confident that the results reflect their patient’s clinical scenario.

“As a physician caring for individuals with inherited bleeding disorders, this development is an exciting advancement in von Willebrand disease diagnostics,” said Johnathan Roberts, MD, of the Bleeding & Clotting Disorders Institute (Peoria, IL, USA), “This assay will reduce some of the diagnostic challenges in caring for individuals with VWD.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.